Abstract

A COMPREHENSIVE REVIEW ON ANALYTICAL METHODS FOR ESTIMATION OF RANOLAZINE IN PHARMACEUTICAL DOSAGE FORMS

Darshangiri B. Gowsami*, Dr. Khushbu Patel, Mrs. Shushila R. Prajapati, Dr. C. N. Patel

ABSTRACT

Ranolazine is a novel anti-anginal agent indicated for the management of chronic stable angina, particularly in patients who remain symptomatic despite conventional therapy. Unlike traditional anti-anginal drugs, ranolazine exerts its therapeutic effect without significantly affecting heart rate or blood pressure, primarily through inhibition of the late inward sodium current in cardiac myocytes. This review presents a concise overview of angina and anti-anginal therapy, followed by a detailed discussion of ranolazine including its chemical structure, mechanism of action, therapeutic applications, and regulatory history. Furthermore, a comprehensive literature review of reported analytical methods for the estimation of ranolazine is provided, covering UV-visible spectrophotometry, derivative spectrophotometry, reverse phase high-performance liquid chromatography (RP-HPLC), liquid–liquid extraction HPLC methods, and high-performance thin-layer chromatography (HPTLC). The compiled analytical data highlight the wide range of techniques employed for quantitative determination of ranolazine in bulk drug, pharmaceutical dosage forms, and biological matrices. This review serves as a useful reference for researchers and analysts involved in pharmaceutical analysis and quality control of ranolazine.

Keywords: Ranolazine; Angina pectoris; Anti-anginal drugs; Late sodium current; UV spectrophotometry; RP-HPLC; HPTLC; Pharmaceutical analysis.